Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging

Area of Science:

• Molecular Biology
• Oncology
• Radiochemistry

Background:

• Cyclin-dependent kinases 4 and 6 (Cdk4/6) regulate cell cycle progression in early G1 phase.
• These kinases are crucial for development, tissue stability, and cancer formation.
• Cdk4/6 are validated targets for novel cancer therapies.

Purpose of the Study:

• To review the therapeutic and diagnostic potential of Cdk4/6 inhibitors.
• To highlight pyrido[2,3-d]pyrimidine derivatives as a promising class of Cdk4/6 inhibitors.
• To discuss their application as anti-cancer agents and radiotracers.

Main Methods:

• Review of recent literature on Cdk4/6 inhibitors.
• Analysis of pyrido[2,3-d]pyrimidine derivatives' chemical structures and biological activities.
• Discussion of radiolabeling strategies for positron emission tomography (PET) imaging.

Main Results:

• Selective small molecule inhibitors of Cdk4/6 have been successfully developed.
• Pyrido[2,3-d]pyrimidine derivatives exhibit significant potential as anti-cancer drugs.
• These compounds can be radiolabeled with 124I and 18F for PET imaging applications.

Conclusions:

• Cdk4/6 inhibitors, especially pyrido[2,3-d]pyrimidine derivatives, represent a dual-purpose approach in oncology.
• They offer a promising avenue for both targeted cancer therapy and non-invasive diagnostic imaging.
• Further research into these inhibitors could advance personalized cancer treatment and monitoring.